Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized study of Fibromun (onfekafusp alfa, L19TNF) versus dacarbazine in previously treated advanced or metastatic soft-tissue sarcoma
2024-512704-20-00Phase 2Authorised
- Sponsor
- Philogen
- Start
- May 2024
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised trial in soft tissue sarcoma (STS) comparing Fibromun arm with Dacarbazine arm (2 arms). Primary endpoint: Progression-free survival. Planned start May 2024; status: authorised.
02
Drugs
onfekafusp alfadacarbazine
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2024-512704-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512704-20-00.